Fig. 3From: Immune characterization of breast cancer metastases: prognostic implicationsOverall survival (OS) according to immune biomarkers assessed on metastasis. OS in the triple-negative cohort according to TILs (a), CD8/FOXP3 ratio (b) and CD8/FOXP3 ratio combined with TILs (c); OS in the HER2+ cohort according to TILs levels (d). CI confidence interval, HR hazard ratio, OS overall survival, TILs tumor-infiltrating lymphocytesBack to article page